Eosinophil-mast cell interaction: Mepolizumab leads to a reduction of clinical symptoms and serum tryptase in a patient with eosinophilic asthma and idiopathic mast cell activation-Reference-Cited by-同舟云学术

Eosinophil-mast cell interaction: Mepolizumab leads to a reduction of clinical symptoms and serum tryptase in a patient with eosinophilic asthma and idiopathic mast cell activation

Published:2021-03 Issue:3 Volume:9 Page:1393-1395.e1
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Guillet Carole,Steinmann Simona,Lang Claudia,Maul Julia-Tatjana,Schmid-Grendelmeier Peter

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference9 articles.

1. Eosinophils and mast cells: a lineage apart;Sarrazin;Nat Immunol,2016

2. Mepolizumab treatment in patients with severe eosinophilic asthma;Ortega;N Engl J Med,2014

3. Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management;Castells;J Allergy Clin Immunol Pract,2019

4. Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm;Leru;Clin Transl Allergy,2019

5. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number;Lyons;Nat Genet,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eosinophils Play a Surprising Leading Role in Recurrent Urticaria in Horses;Vaccines;2024-05-21

2. Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial;British Journal of Clinical Pharmacology;2024-05-07

3. Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons;Cells;2024-02-23

4. The allergic effector unit: From basic science to drug-targetable mast cell–eosinophil interactions in patients;The Journal of Allergy and Clinical Immunology: In Practice;2021-10

5. Reply to “The allergic effector unit: From basic science to drug-targetable mast cell–eosinophil interactions in patients”;The Journal of Allergy and Clinical Immunology: In Practice;2021-10